investor accept in-lin opt stick
around reiter outperform
investor sentiment suggest expect
investor will accept organ growth
line expect beat ep driven
larg non-op tax share rel estim said
compel pipelin new product recent acquisit
converg drive acceler growth
return reiter outperform rate rais tp
catalyst posit drive improv perform
continu strength structur heart includ watchman tavr
sentinel continu build momentum
acceler control launch bsx lotu tavr system
reach wider number center continu expect lotu captur
market share us tavr market end exalt-d
single-us scope anoth key catalyst growth driver expect
launch look expect afib ablat gain increas
momentum compani complet portfolio therapeut cathet
street estim rise august reflect btg four
deal switch organ easier sell day add tailwind
sell day comp get easier sentin nvision nxthera
cryterion begin ad organ growth addit street
estim reflect btg deal close late august
valuat target price base
previous ebitda multipl ebitda bil
bil risk product delay failur progress lt goal litig
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
boston scientif corp global manufactur provid
medic devic equip area vascular intervent
structur heart men women health
price jul rate outperform target price analyst matt miksic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
addit detail takeaway
cardiovascular bil mil y/i cc
intervent cardiolog sale mil mil cc
organ growth quarter led sh mid-teen complex pci growth off-set
continu price pressur de watchman sale ahead plan
avail account manag target launch japan
eu watchman flx transit full launch compani expect launch flx
 tavr acur grew avail
countri lotu edg pace account first month
compani enrol patient repris iv clinic trial expand indic
intermediate-risk patient final sentinel account global
account note sentinel acquisit anniversari juli
manag maintain guidanc sh revenu mil
peripher intervent sale mil mil cc
organ growth driven launch venou stent eluvia
japan strong growth intervent oncolog china manag note
eluvia usag continu post fda paclitaxel panel compani maintain
revis guidanc eluvia mil cut half last quarter
rhythm neuro mil mil y/i cc organ
cardiac rhythm manag sale mil mil cc
organ perform led hsd growth defibril reflect on-going uptak
reson platform heartlog fda approv heart failur
alert system along strong emblem s-icd growth
electrophysiolog sale mil mil cc organ
growth led rhythmia well lumipoint softwar adopt post full launch
compani expect approv polarx cryo-bas system europ end
year lumin rf-base system expect follow
neuromodul sale mil mil cc organ
vercis db strong ou due uptak cartesia
direct lead manag expect mri-label vertiflex
acquisit close june track gener sale mil
medsurg mil mil y/i organ vs
endoscopi sale mil mil cc organ growth
quarter driven number product launch past month includ
spyglass dsii jagwir oris gel endolumin surgeri growth also driven
strong infect prevent sale continu momentum bsx axio stent
improv suppli orcapod singl use valv compani remain track launch
exalt single-us duodenoscop end year
urolog pelvic health sale mil mil cc
organ growth driven mid-teen growth stone franchis strong
lithovu single-us ureteroscop sale across region particularli
em
addit sale spaceoar gel prostat cancer radiat treatment
purchas part augmenix acquisit also strong pace
reach mil year-end compani expect acceler driven
continu lithovu spaceoar strength nxthera augmenix acquisit
anniversari well new product launch
 op margin bp estim bp y/i
sale net cog flat lower non-op lower tax partial off-set
lower sg compani continu expect oper margin rang
bp
compani reiter organ sale growth guidanc includ
bp inorgan contribut nxthera claret augmenix vertiflex
acquisit fx expect neg impact mil compar
guidanc mil previous howev fx expect neutral impact
ep due compani currenc hedg program tax rate
expect compar previous reflect discret tax benefit
 oper tax rate slightli bp benefit
account standard stock compens nearli bp discret tax
benefit
compani expect organ growth plu bp contribut
claret augmenix vertiflex claret acquisit includ organ guidanc
august fx expect mil headwind ep expect
sale
sale
ep
estimate
sale
sale
estimate
chang model
left top-lin estim rel unchang bring ep
estim also made rel minor adjust top-lin
project beyond increas sale estim per year
averag year ep estim decreas
figur chang model
compani mention price
